

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on April 8, 2004..

Joyce Moore  
Name  
Signature *Joyce Moore*



P&G Case 8427

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
Keith Homer Baker, et al. : Confirmation No. 9097  
Serial No. 09/785,876 : Group Art Unit 1751  
Filed February 16, 2001 : Examiner Elsa B. Elhilo

For COMPOSITIONS FOR PRE-TREATING SHOES AND METHODS AND ARTICLES  
EMPLOYING SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☒ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case).** This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☒ (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

OR

☐ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☐ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. \_\_\_\_, U.S. Patent Application Serial No. \_\_, filed \_\_. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR


☐ (4) Copies of all said documents, except Cite Numbers \_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☒ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☐ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☒ Additional information is attached.

Respectfully submitted,

By   
 Jeffrey V. Bamber  
 Attorney or Agent for Applicant(s)  
 Registration No. 31,148  
 (513) 627-4597

Date: April 8, 2004  
**Customer No. 27752**  
 (IDS.doc) (Last Revised 10/10/03)

CONCISE EXPLANATION OF RELEVANCE OF REFERENCES  
NOT IN ENGLISH LANGUAGE

JP 55151099, according to the English language abstract provided herewith, is directed to, among other things, a composition obtained by adding a water-soluble cellulose derivative, to an aqueous detergent solution containing a surfactant together with a builder, fluorescent dyes, blue dyes and fungicide, for cleaning sport shoes.

JP 58067777, according to the English language abstract provided herewith, is directed to, among other things, an agent comprising 5-50 wt.% aq.soln. of (1) starch and (2) water soluble cellulosic high polymer for coating on fabric shoes, such as sport shoes.

EP 0801165, according to the English language abstract provided herewith, is directed to finishing agents for treating textile fibers – contain sugar polymers prepared from acrylic acid and saccharides that contain glucose or can be covered into enolate.

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <div style="text-align: center;"> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p> <p>APR 1 2004</p> <p>SHEET 1 of 1</p> </div>	<p style="text-align: center;"><b>COMPLETE IF KNOWN</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>09/785,876</td> </tr> <tr> <td>Confirmation Number</td> <td>9097</td> </tr> <tr> <td>Filing Date</td> <td>February 16, 2001</td> </tr> <tr> <td>First Named Inventor</td> <td>Keith Homer Baker, et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1751</td> </tr> <tr> <td>Examiner Name</td> <td>E. B. Elhilo</td> </tr> <tr> <td>Attorney Docket Number</td> <td>8427</td> </tr> </table>	Application Number	09/785,876	Confirmation Number	9097	Filing Date	February 16, 2001	First Named Inventor	Keith Homer Baker, et al.	Group Art Unit	1751	Examiner Name	E. B. Elhilo	Attorney Docket Number	8427
Application Number	09/785,876														
Confirmation Number	9097														
Filing Date	February 16, 2001														
First Named Inventor	Keith Homer Baker, et al.														
Group Art Unit	1751														
Examiner Name	E. B. Elhilo														
Attorney Docket Number	8427														

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-4,138,352	02-06-1979	Teot, et al.	
	2	US-4,214,997	07-29-1980	Morris, et al.	
	3	US-4,441,881	04-10-1984	Ruppert, et al.	
	4	US-4,497,919	02-05-1985	Varga, et al.	
	5	US-5,017,237	05-21-1991	Svensson, et al.	
	6	US-5,356,968	10-18-1994	Rupaner, et al.	
	7	US-5,431,840	07-11-1995	Soldanski, et al.	
	8	US-5,599,782	02-04-1997	Pan, et al.	

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	1	GB 1 566 326			04-30-1980			
	2	JP 55151099			11-25-1980			
	3	JP 58067777			04-22-1983			
	4	EP 0 801 165	A2		10-15-1997			
	5	WO 00/65015			11-02-2000			
	6	WO 01/30955	A1		05-03-2001			

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
		ANTHONY J. O'LENICK, JR., Soil Release Polymers; Journal of Surfactants and Detergents; Volume 2, No. 4, October, 1999; AOCS Press, Dacula Georgia	
EXAMINER			DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.